PT - JOURNAL ARTICLE AU - Barbara Clyne AU - Lisa Hynes AU - Colette Kirwan AU - Máire McGeehan AU - Paula Byrne AU - Martha Killilea AU - Susan M. Smith AU - Máirín Ryan AU - Claire Collins AU - Michelle O’Neill AU - Emma Wallace AU - Andrew W Murphy AU - Maureen E Kelly TI - Perspectives on the production, and use, of rapid evidence in decision making during the COVID-19 pandemic: a qualitative study AID - 10.1136/bmjebm-2021-111905 DP - 2022 Jun 30 TA - BMJ Evidence-Based Medicine PG - bmjebm-2021-111905 4099 - http://ebm.bmj.com/content/early/2022/06/30/bmjebm-2021-111905.short 4100 - http://ebm.bmj.com/content/early/2022/06/30/bmjebm-2021-111905.full AB - Objectives To describe perceptions of providing, and using rapid evidence, to support decision making by two national bodies (one public health policy and one front-line clinical practice) during the COVID-19 pandemic.Design Descriptive qualitative study (March–August 2020): 25 semistructured interviews were conducted, transcribed verbatim and thematically analysed.Setting Data were obtained as part of an evaluation of two Irish national projects; the Irish COVID-19 Evidence for General Practitioners project (General Practice (GP) project) which provided relevant evidence to address clinical questions posed by GPs; and the COVID-19 Evidence Synthesis Team (Health Policy project) which produced rapid evidence products at the request of the National Public Health Emergency Team.Participants Purposive sample of 14 evidence providers (EPs: generated and disseminated rapid evidence) and 11 service ssers (SUs: GPs and policy-makers, who used the evidence).Main outcome measures Participant perceptions.Results The Policy Project comprised 27 EPs, producing 30 reports across 1432 person-work-days. The GP project comprised 10 members from 3 organisations, meeting 49 times and posting evidence-based answers to 126 questions. Four unique themes were generated. ‘The Work’ highlighted that a structured but flexible organisational approach to producing evidence was essential. Ensuring quality of evidence products was challenging, particularly in the context of absent or poor-quality evidence. ‘The Use’ highlighted that rapid evidence products were considered invaluable to decision making. Trust and credibility of EPs were key, however, communication difficulties were highlighted by SUs (eg, website functionality). ‘The Team’ emphasised that a highly skilled team, working collaboratively, is essential to meeting the substantial workload demands and tight turnaround time. ‘The Future’ highlighted that investing in resources, planning and embedding evidence synthesis support, is crucial to national emergency preparedness.Conclusions Rapid evidence products were considered invaluable to decision making. The credibility of EPs, a close relationship with SUs and having a highly skilled and adaptable team to meet the workload demands were identified as key strengths that optimised the utilisation of rapid evidence.Ethics approval Ethical approval was obtained from the National Research Ethics Committee for COVID-19-related Research, Ireland.Data are available on reasonable request. The data sets generated and/or analysed during the current study are not publicly available due to privacy/confidentiality concerns. Reasonable requests for access can be made to the corresponding author who will consider any such requests in collaboration with the NREC COVID-19.